-
2024-518384-36-00
4
2020-08-31
Idiopathic membranous nephropathy and severe proteinuria
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-505449-18-00
4
2020-07-23
Patients with relapsed CLL
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2023-506546-23-00
5
2020-05-20
Acute myeloid leukemia
-
2024-516954-24-00
4
2020-05-01
ALS (Amyotrophic Lateral Sclerosis)
-
2024-515408-37-00
4
2020-04-01
glioblastoma multiforme
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-513766-20-00
9
2019-12-03
Hematological malignancies
-
2024-515414-40-00
9
2019-12-01
Heart failure
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-515690-10-00
9
2019-05-10
Follicular B-cell non-Hodgkin's lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-516585-11-00
4
2018-06-12
Advanced melanoma
-
2024-515409-25-00
4
2018-01-11
Chronic myeloid leukemia
-
2024-515413-18-00
4
2017-12-22
Metastatic renal cell carcinoma (mRCC)
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)